Literature DB >> 29874994

Perspectives of Nanoemulsion Strategies in The Improvement of Oral, Parenteral and Transdermal Chemotherapy.

Manisha Pandey1, Hira Choudhury1, Ong C Yeun2, Hoh M Yin2, Tan W Lynn2, Celine L Y Tine2, Ng S Wi2, Kelly C C Yen2, Cheng S Phing2, Prashant Kesharwani3, Subrat K Bhattamisra4, Bapi Gorain5.   

Abstract

BACKGROUND: Targeting chemotherapeutic agents to the tumor tissues and achieving accumulation with ideal release behavior for desired therapy requires an ideal treatment strategy to inhibit division of rapid growing cancerous cells and as an outcome improve patient's quality of life. However, majority of the available anticancer therapies are well known for their systemic toxicities and multidrug resistance.
METHODS: Application of nanotechnology in medicine have perceived a great evolution during past few decades. Nanoemulsion, submicron sized thermodynamically stable distribution of two immiscible liquids, has gained extensive importance as a nanocarrier to improve chemotherapies seeking to overcome the limitations of drug solubilization, improving systemic delivery of the chemotherapeutics to the site of action to achieve a promising inhibitory in tumor growth profile with reduced systemic toxicity. RESULTS AND
CONCLUSION: This review has focused on potential application of nanoemulsion in the translational research and its role in chemotherapy using oral, parenteral and transdermal route to enhance systemic availability of poorly soluble drug. In summary, nanoemulsion is a multifunctional nanocarrier capable of enhancing drug delivery potential of cytotoxic agents, thereby, can improve the outcomes of cancer treatment by increasing the life-span of the patient and quality of life, however, further clinical research and characterization of interactive reactions should need to be explored. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Chemotherapy; active targeting; intravenous chemotherapy; nanoemulsion; oral chemotherapy; transdermalzzm321990chemotherapy.

Mesh:

Substances:

Year:  2018        PMID: 29874994     DOI: 10.2174/1389201019666180605125234

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  A Chitosan-PLGA based catechin hydrate nanoparticles used in targeting of lungs and cancer treatment.

Authors:  Niyaz Ahmad; Rizwan Ahmad; Ridha Abdullah Alrasheed; Hassan Mohammed Ali Almatar; Abdullah Sami Al-Ramadan; Taysser Mohammed Buheazah; Hussain Salman AlHomoud; Hassan Ali Al-Nasif; Md Aftab Alam
Journal:  Saudi J Biol Sci       Date:  2020-05-20       Impact factor: 4.219

Review 2.  Current status of in vivo bioanalysis of nano drug delivery systems.

Authors:  Tingting Wang; Di Zhang; Dong Sun; Jingkai Gu
Journal:  J Pharm Anal       Date:  2020-05-16

3.  Tocotrienols-rich naringenin nanoemulgel for the management of diabetic wound: Fabrication, characterization and comparative in vitro evaluations.

Authors:  Eileen Yeo; Clement Jia Yew Chieng; Hira Choudhury; Manisha Pandey; Bapi Gorain
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-03-14

Review 4.  Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.

Authors:  Manisha Pandey; Neha Jain; Jovita Kanoujia; Zahid Hussain; Bapi Gorain
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

Review 5.  Mucoadhesive Nanocarriers as a Promising Strategy to Enhance Intracellular Delivery against Oral Cavity Carcinoma.

Authors:  Manisha Pandey; Hira Choudhury; Jenifer Ngu Shao Ying; Jessica Foo Sze Ling; Jong Ting; Jocelyn Su Szhiou Ting; Ivory Kuek Zhia Hwen; Ho Wan Suen; Hazimah Syazwani Samsul Kamar; Bapi Gorain; Neha Jain; Mohd Cairul Iqbal Mohd Amin
Journal:  Pharmaceutics       Date:  2022-04-05       Impact factor: 6.525

6.  Nanobiotic formulations as promising advances for combating MRSA resistance: susceptibilities and post-antibiotic effects of clindamycin, doxycycline, and linezolid.

Authors:  Mennatallah A Mohamed; Maha Nasr; Walid F Elkhatib; Wafaa N Eltayeb; Aliaa A Elshamy; Gharieb S El-Sayyad
Journal:  RSC Adv       Date:  2021-12-13       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.